Argenta, a Galapagos NV company, has signed a collaboration agreement with ANTABIO to provide medicinal chemistry, computer-aided drug design and ADME/PK services to assist ANTABIO in the identification and development of novel anti-bacterial agents.    ANTABIO is developing new drugs to work with existing antibiotics to enable them to regain activity against multi- or pan-drug resistant Gram-negative pathogens such as NDM-1 bacteria. ANTABIO’s compounds will also prevent infections caused by vi...